Targeting ubiquitination for cancer therapies

被引:87
|
作者
Morrow, John Kenneth [1 ,2 ]
Lin, Hui-Kuan [3 ]
Sun, Shao-Cong [4 ]
Zhang, Shuxing [1 ]
机构
[1] Univ Texas Houston, MD Anderson Canc Ctr, Dept Expt Therapeut, Integrated Mol Discovery Lab, Houston, TX 77030 USA
[2] Univ Texas Grad Sch Biomed Sci, Houston, TX 77030 USA
[3] Univ Texas Houston, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA
[4] Univ Texas Houston, MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA
关键词
cancer therapeutics; deubiquitinase; E3 ligase inhibition; high-throughput virtual screening; hot spots; in silico modeling; SCF complex; Skp2; inhibitors; small molecule inhibitors; ubiquitination; SMALL-MOLECULE INHIBITOR; ACTIVE PROTEASOME INHIBITOR; SINGLE-AGENT CARFILZOMIB; CELL-CYCLE ARREST; LIGASE CBL-B; MULTIPLE-MYELOMA; OPEN-LABEL; DEUBIQUITINASE INHIBITION; NEDD8-ACTIVATING ENZYME; UBC13-UEV1A INTERACTION;
D O I
10.4155/fmc.15.148
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Ubiquitination, the structured degradation and turnover of cellular proteins, is regulated by the ubiquitin-proteasome system (UPS). Most proteins that are critical for cellular regulations and functions are targets of the process. Ubiquitination is comprised of a sequence of three enzymatic steps, and aberrations in the pathway can lead to tumor development and progression as observed in many cancer types. Recent evidence indicates that targeting the UPS is effective for certain cancer treatment, but many more potential targets might have been previously overlooked. In this review, we will discuss the current state of small molecules that target various elements of ubiquitination. Special attention will be given to novel inhibitors of E3 ubiquitin ligases, especially those in the SCF family.
引用
收藏
页码:2333 / 2350
页数:18
相关论文
共 50 条
  • [1] Targeting the PARylation-Dependent Ubiquitination Signaling Pathway for Cancer Therapies
    Huang, Daoyuan
    Wang, Jingchao
    Chen, Li
    Jiang, Weiwei
    Inuzuka, Hiroyuki
    Simon, David K.
    Wei, Wenyi
    BIOMOLECULES, 2025, 15 (02)
  • [2] Developing Targeted Therapies That Exploit Aberrant Histone Ubiquitination in Cancer
    Jeusset, Lucile M-P
    McManus, Kirk J.
    CELLS, 2019, 8 (02)
  • [3] Therapies for cancer targeting endothelin receptors
    Bagnato, A
    DRUGS OF THE FUTURE, 2003, 28 (10) : 983 - 989
  • [4] Targeting angiogenesis with integrative cancer therapies
    Yance, Donald R., Jr.
    Sagar, Stephen M.
    INTEGRATIVE CANCER THERAPIES, 2006, 5 (01) : 9 - 29
  • [5] Nanotherapy for Cancer: Targeting and Multifunctionality in the Future of Cancer Therapies
    Ediriwickrema, Asiri
    Saltzman, W. Mark
    ACS BIOMATERIALS SCIENCE & ENGINEERING, 2015, 1 (02): : 64 - 78
  • [6] Emerging drug development technologies targeting ubiquitination for cancer therapeutics
    Veggiani, Gianluca
    Gerpe, Maria Carla Rosales
    Sidhu, Sachdev S.
    Zhang, Wei
    PHARMACOLOGY & THERAPEUTICS, 2019, 199 : 139 - 154
  • [7] Resistance to EGFR targeting therapies in lung cancer
    Watzka, S. B.
    Posch, F.
    Hochmair, M.
    Setinek, U.
    Koestler, W. J.
    Mueller, M. R.
    MINERVA CHIRURGICA, 2011, 66 (05) : 483 - 494
  • [8] Understanding and targeting anoikis in metastasis for cancer therapies
    Fard, Farzad Sattari
    Jalilzadeh, Nazila
    Mehdizadeh, Amir
    Sajjadian, Fakhrosadat
    Velaei, Kobra
    CELL BIOLOGY INTERNATIONAL, 2023, 47 (04) : 683 - 698
  • [9] Targeting aldehyde dehydrogenase for prostate cancer therapies
    Ma, Miao
    He, Wenyou
    Zhao, Keyu
    Xue, Linyuan
    Xia, Siyuan
    Zhang, Baotong
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [10] Review of Immune Therapies Targeting Ovarian Cancer
    Fan, Cong
    Reader, Jocelyn
    Roque, Dana M.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2018, 19 (12)